Navigation Links
Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load; Cytoxan Preconditioning Successfully Enhances Engraftment
Date:12/6/2013

lity of single infusions of an escalating dose of an autologous (a patient's own) CD4+ T-cell product genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). Nine HIV-infected subjects (three cohorts of three subjects each) classified as immune non-responders (INR) with sub-optimal T-cell levels and no detectable viral load on long-term ART were enrolled into the trial.  Subjects received SB-728-T at doses of approximately 5, 20 or 30 billion cells and remained on their existing antiviral therapy throughout the study without undergoing a TI.
Cohort 5
Ten HIV-infected subjects heterozygous for the CCR5 delta-32 mutation (i.e. with one CCR5 gene that is naturally modified) who are currently on ART have been enrolled and have received a single intravenous infusion of SB-728-T (12.6 to 23.5 billion cells). Two months after SB-728-T treatment, subjects underwent a 16 week TI during which time their ART was discontinued. ART was reinstituted in subjects whose CD4 T-cell counts dropped to <350 cells/ mm3 and/or whose HIV-RNA increased to >100,000 /mL for three consecutive weekly measurements. At the end of the TI, subjects with a sustained detectable HIV viral load were reinstituted on ART. Subjects with an undetectable viral load can remain off ART until HIV RNA levels are >10,000 copies/mL for three consecutive weekly measurements or their CD4 T-cell count drops below 500 cell/mm3 for two consecutive weekly measurements.

About SB-728-1101
SB-728-1101 is an open-label, dose escalation, multi-center study designed primarily to evaluate the safety and tolerability of escalating doses of cyclophosphamide (Cytoxan) administered prior to SB-728-T infusion. Cytoxan is a drug that is used to transiently reduce the numbers of T-cells in the body, which then rapidly repopulate once the drug is discontinued, and it is into this "growth" environment that SB-728-T is infused. Such lymphodepletive treatment has bee
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
2. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
3. Sangamo BioSciences Reports Fourth Quarter And Full Year 2012 Financial Results
4. Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference
5. Sangamo BioSciences Announces Presentation At The Barclays Global Healthcare Conference
6. Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast
7. Sangamo BioSciences Reports First Quarter 2013 Financial Results
8. Sangamo BioSciences Announces Second Quarter 2013 Conference Call And Webcast
9. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
10. Sangamo BioSciences Reports Second Quarter 2013 Financial Results
11. Sangamo BioSciences Announces Notice Of Allowance For New Patent Application Covering Genome Modification Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... used on patients in order to treat dental impairments, ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its Israeli ... sophisticated agro-breeding solutions for plant breeders and researchers, today ... of directors appointed chemistry and pharmaceutical industry expert Dr. ... the board. From 1975 to 2012, Dr. ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... January 28 ,Amsterdam Molecular Therapeutics (Euronext: AMT), ... therapy, announced today during the Phacilitate Cell ... one treatment of its lead product,Glybera(R) results ... important,lowering of the incidence of acute pancreatitis ...
... Omeros Corporation today announced that it was ... equity and grant funding from The Stanley Medical ... of the Company,s proprietary product candidates for the ... milestone payment to Omeros for having successfully met ...
Cached Medicine Technology:AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly 2AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly 3Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program 2
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- In people with sex ... similar to that seen in drug addicts as they ... clear differences in brain activity between patients who have ... those of drug addicts," study author Dr. Valerie Voon, ... a university news release. Voon,s research involved 19 ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
(Date:7/11/2014)... Ohio (PRWEB) July 11, 2014 As ... 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number of ... blood sugar, abdominal issues and even death from the ... , According to the Times report , a ... in 2013 reported by patients was almost 14% of ...
(Date:7/11/2014)... News) -- Delaying surgery to repair damage to the anterior ... of the knee -- could increase a young athlete,s risk ... records of 130 patients, aged 8 to 16, who had ... than six weeks after their injury, 37 had surgery six ... than three months after their injury. The youngsters who ...
(Date:7/11/2014)... 2014 Riverside Health System became the first ... Virginia in late 2012 and now, in partnership with Williamsburg ... throughout the Williamsburg and Newport News region. , Also known ... benefits to independent older adults who wish to remain in ... net of continuing care services as well as control over ...
Breaking Medicine News(10 mins):Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... In a society that hails monogamy as,the tried and ... that there is a large group of people who ... relationship at a time. Others,are aware of and curious ... to turn to find information or how to look ...
... Net sales $50.8 million, up 25% versus year ago on operating ... historic high commodity costs - Net loss $1.2 million, ... Targeted 30% growth in net sales on operating basis (1), ... today announced its results for the first quarter ended,March 31, 2008. ...
... HIV/AIDS,Policy announced today that the Web site AIDS.gov, a ... now has an innovative look,and feel that incorporates a ... blog ( http://blog.aids.gov ), one of AIDS.gov,s latest features,focuses ... based on,the Internet - in the fight against HIV/AIDS. ...
... condition associated with loss of blood supply to the ... for a type of depression in the elderly related to ... and researchers have discovered why some patients with this condition ... findings were to be presented Wednesday during a news conference ...
... May 7, 2008 ---Alzheimers disease (AD) is an incurable ... even more rapidly as the Baby Boom generation enters ... are only partially effective in some patients. New strategies ... in todays Journal of Neuroscience, researchers in the laboratory ...
... ... - EPS of $0.38, up 36% from first quarter 2007, - Record new business awards of $180 million, up 20% ... 2007, - Total business authorizations of $917 million, ... 2007, CINCINNATI, May 7 ...
Cached Medicine News:Health News:'The Polyamory Handbook': New Guide Covers Entire Spectrum of Rapidly Growing Relationship Style 2Health News:Smart Balance Announces 2008 First-Quarter Results 2Health News:Smart Balance Announces 2008 First-Quarter Results 3Health News:Smart Balance Announces 2008 First-Quarter Results 4Health News:Smart Balance Announces 2008 First-Quarter Results 5Health News:Smart Balance Announces 2008 First-Quarter Results 6Health News:Smart Balance Announces 2008 First-Quarter Results 7Health News:Smart Balance Announces 2008 First-Quarter Results 8Health News:Smart Balance Announces 2008 First-Quarter Results 9Health News:Smart Balance Announces 2008 First-Quarter Results 10Health News:Smart Balance Announces 2008 First-Quarter Results 11Health News:Smart Balance Announces 2008 First-Quarter Results 12Health News:AIDS.gov Goes 2.0: Government HIV/AIDS Website Now Features a Blog, Podcasts, and More 2Health News:Several Therapies Show Promise for Vascular Depression 2Health News:Several Therapies Show Promise for Vascular Depression 3Health News:New target for Alzheimer's disease identified 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 2Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 3Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 4Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 5Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 6Health News:Kendle Delivers Record Net Service Revenues and New Business Authorizations for First Quarter 2008 7
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: